A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy

Published:2016-04-22 Issue:4 Volume:174 Page:571-581
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Goy Andre¹,Forero Andres²,Wagner-Johnston Nina³,Christopher Ehmann W.⁴,Tsai Michaela⁵,Hatake Kiyohiko⁶,Ananthakrishnan Revathi⁷,Volkert Angela⁸,Vandendries Erik⁹,Ogura Michinori¹⁰¹¹

Affiliation:

1. John Theurer Cancer Center; HUMC; Hackensack NJ USA

2. University of Alabama at Birmingham; Birmingham AL USA

3. Washington University School of Medicine; St. Louis MO USA

4. Penn State Hershey Cancer Institute; Hershey PA USA

5. Minnesota Oncology; Minneapolis MN USA

6. Cancer Institute Hospital; Tokyo Japan

7. Inventiv Health; Cambridge MA USA

8. Pfizer Inc; New York NY USA

9. Pfizer Inc; Cambridge MA USA

10. Nagoya Daini Red Cross Hospital; Nagoya Japan

11. Tokai Central Hospital; Kakamigahara Gifu Japan

Funder

Pfizer

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14094/fullpdf

Reference39 articles.

1. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study;Advani;Journal of Clinical Oncology,2010

2. A phase II study of weekly inotuzumab ozogamicin (InO) in adult patients with CD22-positive acute lymphoblastic leukemia (ALL) in second or later salvage;Advani;Blood,2014

3. Differential expression of CD22 in indolent and aggressive non-Hodgkin's lymphoma (NHL): implications for targeted therapy;Cesano;Blood,2002

4. Current approaches to therapy for indolent non-Hodgkin's lymphoma;Cheson;Oncology,1998

5. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group;Cheson;Journal of Clinical Oncology,1999

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions;Cancer;2024-08-02

2. Bifunctional molecular probe targeting tumor PD-L1 enhances anti-tumor efficacy by promoting ferroptosis in lung cancer mouse model;International Immunopharmacology;2024-03

3. Innovations in Antibody-Drug Conjugate (ADC) in the Treatment of Lymphoma;Cancers;2024-02-18

4. The Non-hodgkin Lymphoma Treatment and Side Effects: A Systematic Review and Meta-analysis;Recent Patents on Anti-Cancer Drug Discovery;2024-02

5. Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review;Current Cancer Therapy Reviews;2024-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3